TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ).
CARsgen Therapeutics Holdings Ltd. reported its interim financial results for the first half of 2025, highlighting a revenue of RMB51 million primarily from its BCMA CAR T-cell product. The company achieved a significant reduction in net loss to RMB75 million, a decrease of RMB277 million compared to the same period in 2024, driven by increased gross profit and reduced expenses. Despite a decrease in cash reserves, CARsgen expects to maintain adequate cash flow into 2028, demonstrating improved financial health and operational efficiency.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company focused on innovative CAR-T cell therapies. The company specializes in developing and commercializing autologous CAR-T cell products, primarily targeting cancer treatments, with a strong emphasis on cost-effective manufacturing processes.
Average Trading Volume: 3,043,148
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.81B
See more insights into 2171 stock on TipRanks’ Stock Analysis page.